Impact on survival benefits of asymptomatic primary tumor resection after bevacizumab plus FOLFIRI as first-line therapy for patients with metastatic colorectal cancer with synchronous unresectable metastasis
International Journal of Colorectal Disease · 2024
DOI: 10.1007/s00384-024-04745-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Colorectal Disease, 2024. Verfasst von Yen-Cheng Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, 80708, Taiwan. Hauptthemen laut MEDLINE: Bevacizumab, Colorectal Neoplasms, Leucovorin, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, 80708, Taiwan.
- Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, No. 100 Tzyou 1st Road, Kaohsiung, 80708, Taiwan.
- Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, 80708, Taiwan.
- Department of Surgery, Faculty of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, 80708, Taiwan.
- Division of Trauma and Surgical Critical Care, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, 80708, Taiwan.
- Department of Emergency Medicine, Faculty of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, 80708, Taiwan.
Zitieren
APA
Chen, Y. C., Chang, T. K., Su, W. C., Yeh, Y. S., Chen, P. J., Huang, P. J., Yang, P. H., Tsai, H. L., Wang, J. Y., & Huang, C. W. (2024). Impact on survival benefits of asymptomatic primary tumor resection after bevacizumab plus FOLFIRI as first-line therapy for patients with metastatic colorectal cancer with synchronous unresectable metastasis. International Journal of Colorectal Disease. https://doi.org/10.1007/s00384-024-04745-1
Vancouver
Chen YC, Chang TK, Su WC, Yeh YS, Chen PJ, Huang PJ, et al. Impact on survival benefits of asymptomatic primary tumor resection after bevacizumab plus FOLFIRI as first-line therapy for patients with metastatic colorectal cancer with synchronous unresectable metastasis. International Journal of Colorectal Disease. 2024. doi:10.1007/s00384-024-04745-1
BibTeX
@article{Chen2024,
author = {Chen, Yen-Cheng and Chang, Tsung-Kun and Su, Wei-Chih and Yeh, Yung-Sung and Chen, Po-Jung and Huang, Peng-Jen and Yang, Po-Hsiang and Tsai, Hsiang-Lin and Wang, Jaw-Yuan and Huang, Ching-Wen},
title = {Impact on survival benefits of asymptomatic primary tumor resection after bevacizumab plus FOLFIRI as first-line therapy for patients with metastatic colorectal cancer with synchronous unresectable metastasis},
journal = {International Journal of Colorectal Disease},
year = {2024},
doi = {10.1007/s00384-024-04745-1}
}
EUVIMED